Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

  • New branded recognition will spotlight the care, innovation and grit of U.S. healthcare professionals making a meaningful difference for patients, colleagues and communities.
  • The collaboration will recognize healthcare leaders helping strengthen care amid growing pressure on health systems.
  • Nominations will open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026.

Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all.

Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, a branded award, will open July 16, 2026 at www.jnj.com/healthcare-champion-of-the-year and close by 5:00 p.m. ET on August 28, 2026. The honoree will be announced leading up to TIME's "A Year in TIME" celebration, which will take place on December 9, 2026 in New York City.

Recognizing the People Shaping Health Itself

The new Healthcare Champion of the Year award will honor individuals who are shaping the future of health.

Across the country, healthcare professionals are navigating a series of the most consequential moments in healthcare. When healthcare systems are under strain, leadership at the point of care matters. It can change how a patient experiences a diagnosis, how a team pushes through pressure and how a community gets connected to care. Through this partnership, Johnson & Johnson and TIME will shine a light on healthcare leaders whose care, innovation and grit are helping make better care possible.

"At Johnson & Johnson, Our Credo begins with our responsibility to patients, doctors, nurses and all others who use our medicines and medical technology. That responsibility guides how we show up for the people at the heart of care," said Vanessa Broadhurst , Executive Vice President, Global Corporate Affairs, Johnson & Johnson. "Healthcare professionals bring skill, compassion and resolve to some of the most important moments in people's lives. With the Healthcare Champion of the Year Award, we proudly recognize those whose compassion, innovation, and grit are transforming patient care today and building a healthier tomorrow."

Why this Recognition Matters

Healthcare is advancing rapidly, yet gaps in access to quality care persist. The Healthcare Champion of the Year award is designed to spotlight impact, recognizing what becomes possible when healthcare professionals are supported and empowered to lead change where it matters most.

The recognition builds on Johnson & Johnson's long-standing commitment to improving health outcomes by championing nursing and a thriving health workforce. Through J&J CareCommunity, the company's global social impact platform, J&J helps equip nurses and community health workers with the skills, resources, and connections they need to strengthen health systems, expand access to care, and improve health outcomes in communities around the world. Together, these efforts reflect a simple belief: the future of healthcare depends on recognizing, elevating and supporting the people who strengthen patient care every day.

How to Submit a Nomination

Eligible nominees may include physicians, nurses, advanced practice clinicians, surgeons, community health workers, care navigators and other healthcare professionals actively involved in clinical care or care delivery in the United States.

Nominees may be at any stage of their career and should demonstrate real-world impact by how they show up for patients, colleagues and communities. Nominations should reflect at least one of the program's core themes: grit, innovation or patient care.

Nominations will open July 16, 2026 and close by 5:00 p.m. ET on August 28, 2026. The winner will be selected by Johnson & Johnson and a panel of Johnson & Johnson-selected industry experts.

To learn more or submit a nomination, visit https://www.jnj.com/healthcare-champion-of-the-year . Terms and conditions apply: https://www.jnj.com/healthcare-champion-of-the-year/terms-and-conditions .

Johnson & Johnson's Commitment to the Global Health Workforce

As healthcare advances, we believe in supporting those who shape it – healthcare professionals. J&J CareCommunity is a global social impact platform from Johnson & Johnson to advance access to quality care through championing nurses and community health workers. We do this by collaborating with those closest to the challenge to connect more people to care. Learn more at www.jnj.com/jnjcarecommunity.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ .

Media contact:
Trish Garrity
tgarrity@ITS.JNJ.com
202-951-0265

News Provided by Business Wire via QuoteMedia

JNJ
The Conversation (0)
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global... Keep Reading...
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition,... Keep Reading...
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at... Keep Reading...

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). As quoted in the press release: The collaboration will explore the potential for Kaleido’s... Keep Reading...

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech. As quoted in the press release: Upon closing, Janssen paid XBiotech $750 million, with $75 million held in escrow for 18 months. Should Janssen pursue... Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell's pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell's ongoing pivotal Phase 3 study in metastatic breast cancer briacell... Keep Reading...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...

Interactive Chart

Latest Press Releases

Related News